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Abstract: In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular 
medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases. 
Medicine and drug development have seen a paradigm shift which can be characterized with the catchword “persona-
lized medicine”, also called “stratified medicine” or “precision medicine”. Personalized medicine is based on defined 
tandems of therapeutic agents and diagnostic tests. With this addition to the regular medical examination of the patient, 
specific patient characteristics are determined. The results of such diagnostic tests are then decisive for the choice of 
therapy or control of the effectiveness of the chosen treatment. The benefit of personalized medicine for the patient is 
the higher probability of treatment success as well as improved effectiveness and reduced / avoided side effects. Health 
insurance systems and the public may have the advantage that the health funds can be used more efficiently on this basis. 
This new paradigm requires also a new debate on the remuneration in health care. In order to bring personalized thera-
pies to patients as quickly as possible, all players in health care should work together to address the challenges asso-
ciated with personalized medicine. 
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Introduction 
rug research has changed fundamentally in 
recent decades. Thanks to a significantly bet-
ter and more in-depth understanding of phy-
siological and pathophysiological processes, molecu-
lar medicine has developed. This not only allowed 
a better understanding of disease processes but also 
provided knowledge regarding diagnostic and thera-
peutic measures on a molecular level. 
As a result, the number of treatable diseases has in-
creased significantly. The possibilities for differen-
tiating between different indications and their 
sub-specialties have led to an armamentarium of new 
diagnostic and therapy options that was unthinkable 
20 years ago. This applies both to the optimization of 
efficacy and the reduction/avoidance of undesirable 
side effects. 
Thanks to the findings obtained and specialization, 
we can now work towards identifying the most suita-
ble therapy for an individual patient — and in the cor-
rect dosage. Because the diagnostic and the therapeu-
tic principle can be brought together on a molecular 
level — often through intervention on an identical 
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molecular target — we can now describe modern drug 
therapy as a step on the way to personalized medicine. 
In other words, medicine for various clearly identifia-
ble patient subgroups based on highly specialized di-
agnoses as well as highly differentiated therapies both 
in quantitative and qualitative terms. Ideally, a specific 
diagnostic test to determine molecular characteristics 
should be carried out as part of regular patient exami-
nations. The result of this test would then make it eas-
ier to decide on an appropriate therapy. The diagnosis 
and therapy should be so well matched that we can 
refer to a tandem comprising the therapeutic agent and 
diagnostic test. 
In other cases, relevant parameters for metaboliza-
tion or, more generally speaking, for the pharmaco-
dynamics of the medicine are collected in order to 
adjust the dosage adequately. All these cases come 
under the heading of “personalized medicine”, i.e., an 
optimized or differentiated therapy. For the research-
based pharmaceutical and biotech industry and, in 
particular, for the doctor providing treatment, the 
challenges arising from this new understanding of 
personalized medicine are huge. Not surprisingly, this 
new paradigm also creates a need for a new debate 
regarding remuneration for health care services. 
The article which follows will attempt to show 
what possibilities already exist today and what chal-
lenges — with a special focus on the German perspec-
tive — need to be addressed. The aim should be to 
make the idea of personalized medicine based on mo-
lecular findings a success — the success that patients 
need and the success we should be striving to achieve 
throughout the health care sector. 
The Term “Personalized Medicine” 
There are numerous definitions of personalized medi-
cine, some of which are imprecise. These include “in-
dividualized medicine”[1], “stratified medicine”[2], “pr-
ecision medicine”[3] and many others. In the present 
article, the term personalized medicine will be used. 
The research-based pharmaceutical and biotech in-
dustry understands personalized medicine as defined 
tandems comprising a drug and a diagnostic test 
which lead to a differentiated therapy geared to indi-
vidual patient groups rather than a diagnosis alone[4,5]. 
With the help of diagnostic tests, patients in need of 
therapy are subdivided into various patient groups: (i) 
patients for whom a specific medicine is an option, (ii) 
patients unlikely to benefit and (iii) patients who may 
experience serious side effects as a result of taking the 
medicine (e.g., because of a metabolic disorder). An 
alternative therapy must therefore be used for the last 
two patient groups (Figure 1). In light of this, the var-
ious therapy options are given a type of “suitability 
criterion”.  
 
 
 
Figure 1. The principle of personalized medicine: On the 
whole, all patients exhibit the same or very similar symptoms. 
However, the diagnostic test shows that only some of the pa-
tients (the green ones here) would really benefit from taking 
medicine A. For certain patients (the yellow ones here), it be-
comes clear that they are non-responders to the medicine. 
These patients would not benefit from taking medicine A. The 
doctor therefore prescribes them medicine B. With the last 
group, there is a risk of unacceptable side effects. These pa-
tients too are then offered an alternative therapy option. 
 
In order to identify this “suitability criterion” for 
the various therapy options, a diagnostic test (or pos-
sibly several tests) is carried out in addition to the 
regular medical examination of the patient to deter-
mine patient characteristics. These are then taken into 
account when choosing a therapy or checking progress. 
The test is designed to help choose a suitable therapy 
in each case and/or to determine the optimum dosage 
and possibly to check progress during therapy. A bio-
marker test can be used to check for the presence of 
specific gene alleles, gene expression patterns or bioc-
hemical parameters in blood or in other tissues and bo-
dily fluids. The results of an examination using tech-
nical equipment can also make a contribution here. 
The term “personalized medicine” therefore de-
scribes the targeted stratification of patient groups and 
is thus synonymous with “stratified medicine”, anoth-
er term used. The basic idea of keeping an eye on the 
patient and their particular needs when choosing a 
therapy is not what is new. After all, the knowledge 
and experience of the doctor providing treatment have 
always played a decisive role in diagnosing and treat-
ing illnesses. What is actually new about personalized 
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medicine is the fact that doctors are increasingly 
choosing therapeutic procedures using modern mole-
cular diagnostic tools, taking into account the mole-
cular basis/circumstances of the patient’s or patient 
group’s illness. This increases the efficacy of the 
treatment and unwanted side effects are either reduced 
(e.g., because the doctor knows a potential risk in ad-
vance and can include an additional therapy to treat 
the side effects before they show up) or avoided alto-
gether (e.g., because of a metabolic disorder of the 
patient). The efficacy and tolerance of a medicine can 
also be predicted reliably for individual patients. 
Doctors can therefore make therapy decisions on an 
even broader, sounder basis. 
Personalized medicine is thus a direct consequence 
of the achievements of modern biomedical research 
and, on the basis of these findings, the logical next 
step when diagnosing and treating illnesses. Thanks to 
progress in clarifying the genetic and biochemical 
causes of various illnesses, new molecular starting 
points are increasingly being identified. When applied 
to personalized medicine, these optimize the efficacy 
of medicines while reducing their side effects. 
Consequences for Drug Development and 
Therapy 
When work to develop personalized medicine began, 
looking for genetic or other markers for personalizing 
therapy was usually done later on. In some cases, it 
was not done until years after the therapy itself was 
introduced. Nowadays, this is an established step in 
many research and development programs. The clini-
cal trials recorded in the international study register 
www.clinicaltrials.gov show that the use of biomark-
ers has increased significantly over the past 20 years — 
from approx. 4% before 1990 to 20% of all indus-
try-sponsored trials in the years since 2005 (Figure 
2A)[4]. An internal survey of vfa member companies 
also revealed that this figure in its trials could be as 
high as 40%[6]. This clear increase is confirmed by a 
further survey[7] (Figure 3) where the use of biomark-
ers for oncological trials rose from 19% in 2002 to 43% 
in 2013.  
These figures show that research-based pharma-
ceutical and biotech companies are investing signifi-
cantly in pharmacogenetics and other biomarker activ-
ities which provide an important basis for developing 
personalized medicine. Naturally, it is essential that 
informative, validated biomarkers with an appropriate 
level of sensitivity and specificity are available. Oth-
erwise, the relevant medicine could be given to a pati-
ent for whom it is not suitable or patients could miss 
out on a suitable therapy. In contrast, the type of biom-
arker is of secondary importance. There is a broad 
range here — from clinical, genetic and biochemi-
cal biomarkers to results from imaging procedures. 
 
 
 
Figure 2. Significant increase in the use of biomarkers in clinical trials since 1990 — main focus on phase I and phase II trials; da-
ta basis: industry-sponsored active ingredient trials from http://www.clinicaltrials.gov (approx. 30,000 trials since ~1970); as at: Feb-
ruary 2011; source: http://www.clinicaltrials.gov, BCG analysis[4] 
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Figure 3. Significant increase in the use of biomarkers in clinical trials during the period from 2002 to 2013; data basis: evaluation in 
Citeline Trialtrove©; as at January 2014; source: Citeline Report[7] 
 
When carrying out such clinical trials using this 
new therapy principle, there are however new chal-
lenges. These relate in particular to study planning and 
design, recruitment (many patients need to be “scre-
ened” before taking part in the trials) and carrying out 
such trials in general. 
At the moment, biomarkers are most commonly 
used in the clinical phase II[4] (Figure 2B). In this 
phase, the efficacy of a medicine is checked with pa-
tients for the first time. In contrast, the use of bio-
markers falls again in phases III and IV because this 
approach does not really benefit all medicines where 
personalization was originally researched. Indica-
tion-specific differences too are likely here.  
All in all, these figures show that attempts are made 
to identify the patient groups who will benefit most 
from a therapeutic approach on the basis of pre-cli-
nical findings early on in drug development. 
Given the growing importance of diagnostics for 
personalized medicine, the research and development 
activities for new therapies which are already complex 
are set to become even more difficult and complex. 
Building up or acquiring diagnostic expertise for med-
icine development is therefore of particular relevance, 
whether it be in-house or via partnerships. One of the 
key problems is validating potential biomarkers. Bet-
ter linking the results of basic research to clinical 
findings from well characterized patient cohorts is 
therefore important for the future. In Germany for exa-
mple, work to establish a National Cohort (NAK-
O)[8] based on 200.000 people aged 20–69 years from 
all over the country began in 2014. This should hope-
fully provide new impetus for identifying and validat-
ing new markers.  
In order to make progress here, the transfer of kno-
wledge must be further improved and new forms of 
collaborations, partnerships and joint approaches betw-
een academia, pharmaceutical and biotech companies, 
diagnostic manufacturers, IT firms, service providers, 
approval authorities and HTA institutions need to be 
found. 
Status Quo 
As expected, oncology currently has the largest pro-
portion of trials with biomarker checking — around 
50%[4]. Biomarkers are used in more than one in three 
oncological trials (37%[4] and 43%[7]). Other important 
areas of use are cardiovascular and muscular diseases 
as well as immunology (Figure 4). Progress when it 
way for personalized medicine in other indication 
comes to molecular differentiation, in particular for 
oncological and immunological diseases, is paving the 
areas too. And personalized medicine is by no means a 
distant dream: in Germany, 48 drugs (Figure 5 and 
Table 1)[9] which may or should only be used in ac-
cordance with the described personalized medicine 
concept, i.e., following an appropriate pre-test, are 
currently approved. 
Why is Personalized Medicine Important? 
With the therapies previously available, it is known  
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Figure 4. Oncology is a pioneer when it comes to the use 
of biomarkers; data basis: industry-sponsored active ingredient 
trials from http://www.clinicaltrials.gov (approx. 30,000 trials 
since ~1970 until February 2011); source: 
http://www.clinicaltrials.gov, BCG analysis[4] 
that not every patient will respond or respond suffi-
ciently to a medicine and could even experience side 
effects. In contrast, personalized medicine can give an 
indication of the correct dosage, tolerance and efficacy 
of a medicine by providing information about indi-
vidual patient needs, e.g., specific enzymes required to 
dismount a drug’s active ingredient. Personalized 
medicine methods fit into the range of diagnostic in-
struments available to doctors — from standard med-
ical examinations and various diagnostic methods (e.g. 
laboratory tests, imaging) to an increasingly specific 
identification of diseases in light of the molecular cir-
cumstances behind the relevant patient’s illness.  
The doctor can increase the effectiveness of treat-
ment thanks to the latest diagnostics and the subse-
quent use of new therapeutic procedures geared to the 
needs of the patient. Unwanted side effects can also be 
avoided or at least be reduced for the benefit of the 
patient. 
 
 
Figure 5. The number of active ingredients used in Germany with mandatory or recommended personalization in various areas of 
application — the majority of them are currently used in oncology[9]. 
 
Table 1. Explanation using Abacavir as an example: obligatory test for the presence of the HLA-B*5701 allele which increases the 
risk of possible serious side effects. In the event of a positive test result (approximately 5% of all patients), the drug will not be used. 
[Source: vfa research (see http://www.vfa.de/personalisiert.de)] 
Active Ingredient Indication Test for.... Mandatory Test? 
Abacavir HIV Side effects Mandatory 
Afatinib Lung cancer Efficacy Mandatory 
Anastrozol Breast cancer Efficacy Mandatory 
Arsentrioxid Leukemia Efficacy Mandatory 
Ataluren Muscular diseases Efficacy Mandatory 
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(Continued) 
Active Ingredient Indication Test for.... Mandatory Test? 
Azathioprin Transplants Side effects Recommended 
Blinatumomab ALL Efficacy Mandatory 
Bosutinib CML Efficacy Mandatory 
Brentuximabvedotin Lymphoma Efficacy Mandatory 
Carbamazepin Epilepsy Side effects Recommended 
Ceritinib Lung cancer Efficacy Mandatory 
Cetuximab Bowel cancer Efficacy Mandatory 
Cobimetinib Melanoma Efficacy Mandatory 
Crizotinib Lung cancer Efficacy Mandatory 
Dabrafenib Melanoma Efficacy Mandatory 
Dasatinib CML/ALL Efficacy Mandatory 
Eliglustat Gaucher’s disease Efficacy Mandatory 
Erlotinib Lung cancer Efficacy Mandatory 
Everolimus Breast cancer Efficacy Mandatory 
Exemestan Breast cancer Efficacy Mandatory 
Fulvestrant Breast cancer Efficacy Mandatory 
Gefitinib Lung cancer Efficacy Mandatory 
Ibrutinib CLL Efficacy Mandatory 
Imatinib ALL/CLL Efficacy Mandatory 
Ivacaftor Cystic fibrosis Efficacy Mandatory 
Lapatinib Breast cancer Efficacy Mandatory 
Letrozol Breast cancer Efficacy Mandatory 
Lomitapid Hypercholesterolemia Efficacy Recommended 
Lumacaftor/Ivacaftor Cystic fibrosis Efficacy Mandatory 
Maraviroc HIV Efficacy Mandatory 
Mercaptopurin Leukemia Side effects Recommended 
Migalastat Fabry’s disease Efficacy Mandatory 
Natalizumab Multiple sclerosis Side effects Recommended 
Necitumumab Non-small-cell lung cancer Efficacy Mandatory 
Nilotinib CML Efficacy Mandatory 
Olaparib Ovarian cancer Efficacy Mandatory 
Osimertinib Non-small-cell lung cancer Efficacy Mandatory 
Oxcarbazepin Epilepsy Side effects Recommended 
Panitumumab Bowel cancer Efficacy Mandatory 
Pertuzumab Breast cancer Efficacy Mandatory 
Ponatinib ALL Efficacy Mandatory 
Tamoxifen Breast cancer Efficacy Recommended 
Toremifen Breast cancer Efficacy Mandatory 
Trametinib Melanoma Efficacy Mandatory 
Trastuzumab Breast cancer Efficacy Mandatory 
Trastuzumabemtansin Breast cancer Efficacy Mandatory 
Vandetanib Thyroid cancer Efficacy Recommended 
Vemurafenib Skin cancer Efficacy Mandatory 
Source: vfa research (see http://www.vfa.de/personalisiert.de); as at: July 18th, 2016 
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Thus, the patient will benefit from personalized 
medicine as the therapy is more likely to be effective 
and patients will more likely tolerate the drug admi-
nistered. Ideally, ineffective treatments for patients not 
responding to treatment (non-responders) or therapies 
which need to be aborted prematurely owing to into-
lerances can be avoided. This is particularly important 
as many personalized drugs are currently used to treat 
serious and chronic illnesses.  
What are the Challenges of Being Successful 
with Personalized Medicine? 
The personalized medicines that are being developed 
or are already available show that there is a high level 
of inventiveness and innovation when it comes to 
academic activities in the field of biomedical science 
and in pharmaceutical and biotech companies. The 
scientific and technical requirements when developing 
this new branch of molecular medicine are very com-
plex and resource-intensive. 
Given the growing number of biomarkers and indi-
vidual therapy options, the importance of personalized 
medicine is increasing. Therefore a challenge for the 
doctor is coming up too — keeping track of the ever 
more complex tests and therapy options. Owing to 
progress in research into the molecular causes of ill-
nesses, the information base will grow continually. In 
light of this, ways must be found to cope with increa-
singly complex information. This is the case for ex-
ample if a number of biomarkers to be tested and/or 
other diagnostic parameters need to be recorded for an 
illness at the same time.  
In order to be able to compare patient profiles and 
the medication required quickly and reliably in spite 
of the increasing complexity of day-to-day medical 
work, quality-assured, high-performance and learn-
ing-capable Internet-based platforms are needed. With 
such platforms, a large number of therapies — even 
those with a complex biomarker background — could be 
personalized reliably and thus optimized in the future. 
These platforms must be stable, systematically up-
dated and independently validated. Innovative IT 
platforms will play an important role in ensuring that 
personalized medicine becomes more widespread. 
On the scientific side, efforts must be made to drive 
forward the identification and clinical validation of 
new biomarkers in order to be able to develop new 
personalized medicine approaches in the future too. 
The validation of biomarkers is essential when it 
comes to ensuring broad, reliable use of personalized 
medicine and requires significant use of resources on 
the part of research-based pharmaceutical and biotech 
companies. 
There will also be further challenges affecting all 
areas. These include basic research (e.g., biomarker 
research, biobanks), clinical research (e.g., study plan-
ning/designs, screening a large number of patients in 
order to identify the few ones who are suitable for the 
chosen approach) and communicating with ethics 
commissions and patients until approval is given.  
Specific Problems in Germany? 
While the potential of personalized medicine is scien-
tifically acknowledged, there are serious problems in 
Germany, in particular regarding remuneration for 
diagnostic tests which form the basis for the correct 
use of drugs with a recommended or prescribed test. 
At the moment, the tandem comprising diagnostic test 
and therapeutic agent still ends upon approval. The 
drug is approved as part of an official procedure and, 
when launched on the market, is initially paid for by 
the statutory health insurance system. Its addition-
al benefit identified during the early benefit assess-
ment must then be proven and a reimbursement price 
negotiated with the statutory health insurance system.  
If a specific diagnostic test is required for a drug, 
the test must first be validated, a CE marking must be 
obtained and the test must be registered with the Ger-
man Institute for Medical Documentation and Infor-
mation (DIMDI). It will then be allowed on the mar-
ket but will not be immediately reimbursable. An as-
sessment procedure involving the joint self-admini-
stration of the statutory health insurance system and 
the medical profession then takes place. This laborious 
procedure can take up to six years. In the meantime, 
the drugs can already be used and the doctors (or their 
patients) are left to deal with the unanswered question 
as to whether or not the required diagnostic test 
will be reimbursed. And even after the test had rea-
ched this status, in many cases diagnostic tests are still 
challenged or will be replaced by new (and e.g., more 
reliable) approaches.  
Those responsible for health care policy must 
therefore ensure suitable conditions for personalized 
medicine. The additional benefits of personalized 
drugs should therefore be acknowledged during the 
early benefits assessment — naturally on the basis of 
medical evidence and validated diagnostic tests. Steps 
must also be taken to ensure reasonable and imme-
diate reimbursement of the costs of personalized drugs 
Personalized medicine: consequences for drug research and therapy 
 
8 Advances in Precision Medicine, vol 1, issue 2, 2016 
and diagnostic tests.  
In Germany, some progress is being made in this 
area. With the new doctors' fee schedule (EBM) 
guidelines which came into force on July 1st, 2016[10], 
a number of tests have been explicitly approved for 
reimbursement. 1st of July 2016 could have actual-
ly been a good day for personalized medicine. When 
the revised version of the EBM came into force, com-
panion diagnostics (CDx) which indicate a response to 
lifesaving cancer drugs were for the first time given 
their own reimbursement code — and tumorigenesis 
examinations were even given a new chapter of their 
own (19.4). The Federal Association of Statutory 
Health Insurance Physicians (KBV) and the Central 
Association of Statutory Health Insurance Companies 
(GKV-Spitzenverband) who were responsible for the 
revision thus sent out a positive signal. 
However, reimbursement by the health insurance 
system in Germany was explicitly ruled out for the 
liquid biopsy approach which is currently being pro-
moted intensively on a scientific level. Two sentences 
in relatively simple legal language which precede the 
newly created Chapter 19.4 are causing concern for 
providers of molecular cancer therapies and the asso-
ciated diagnostic tests: “The fee schedule items in 
Section 19.4 of the EBM may only be invoiced for 
in-vitro diagnostic tests for tumor genetic changes in 
neoplastically transformed tissues and organs. Ana-
lyses of free nucleic acids in plasma and gene expres-
sion analyses other than tests carried out under fee 
schedule item 19435 [blood cancer but not solid tu-
mors] are not billable.” This means that contracted 
doctors can only invoice invasive tissue biopsy-based 
CDx tests. In contrast, liquid biopsy tests which are 
relatively inexpensive and patient friendly as they are 
non-invasive are excluded — even though they have 
already been approved for use on the market. This is 
detrimental to patients in Germany and will hinder the 
spread of personalized medicine. 
However, there are still reasons to remain hopeful — 
the German Federal Government’s “Pharma Dialog” 
was concluded in April 2016[11]. It states that diagnos-
tic procedures as part of personalized medicine 
“should be better reimbursed” in the future. A draft bill 
which may address the reimbursement problems is 
expected to be published in summer 2016. 
The problem of reimbursement diagnostic proce-
dures is not the only issue which needs to be ad-
dressed. Those who provide the medical service must 
also be compensated for the extra work involved in 
diagnosing an illness and explaining it to patients. A 
dedicated infrastructure for genetic data for example 
would be beneficial here. This would rule out possible 
multiple testing and could thus help to ensure cost- 
efficiency. A dedicated diagnostic infrastructure made 
up of regional diagnostic centers should be set up 
across the country. This already happened in France. It 
is not without reason that France is the European lea-
der when it comes to carrying out such trials[7]. Re-
search and the use of personalized therapy approaches 
as part of day-to-day therapy would benefit equally 
from this. After all, regional diagnostic centers of this 
type allow the proper validation of all diagnostic tests 
used and quality assurance, e.g., through standardiza-
tion. This can also significantly reduce the risk of false 
positive or false negative test results — ensuring reli-
able results for the patient, the doctor providing treat-
ment and research. Such centers can also feature vir-
tual elements. 
Furthermore, the full potential of personalized 
medicine can only be realized if the doctor has suffi-
cient time and resources to carry out more complex 
analyses, to interpret them and to assess them. Ulti-
mately, the patient should not have to deal with possi-
bly complex information alone, for example if they 
find out that a new medicine is not an option for them 
owing to the molecular characteristics of their illness. 
Here too, doctors play a special explanatory and advi-
sory role which must be supported and rewarded ac-
cordingly. 
Acceptable legal conditions and a positive percep-
tion of the necessary genetic tests by politicians and 
the public are further requirements when it comes to 
the practical use of personalized medicine.  
Conclusion 
Many challenges still need to be addressed in order to 
establish personalized medicine as part of everyday 
medicine and to take advantage of the opportunities 
for patients[12]. Logically, everyone involved in the 
health care system should tackle the challenges pos-
ed by personalized medicine together. In future, more 
personalized therapies could be possible, allowing 
the best possible patient care including more efficient 
use of the available resources. 
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